Skip to content
naulon
Not checkedNot checked for notices yet.

Use of sevelamer in chronic kidney disease: beyond phosphorus control

Laura Rodríguez-Osorio, Diana Pazmiño Zambrano, Carolina Gracia-Iguacel and 4 more

Nefrología (English Edition) · 2015

doi:10.1016/j.nefroe.2015.05.011 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Sevelamer is a non-calcium phosphate binder used in advanced chronic kidney disease (CKD) and in dialysis for hyperphosphataemia control. Several experimental, observational studies and clinical trials have shown that sevelamer has pleiotropic effects, beyond hyperphosphataemia control, including actions on inflammation, oxidative stress, lipid profile and atherogenesis, vascular calcification, endothelial dysfunction and the reduction of several uremic toxins. This is the biological basis for its global effect on cardiovascular morbidity and mortality in patients with chronic kidney disease. This review focuses on these pleiotropic actions of sevelamer and their impact on cardiovascular health, with the experience published after more than ten years of clinical expertise.

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.